Sierra Sciences, Inc.

Lancer K Brown

William H Andrews

Laura A Briggs

Hamid Mohammadpour

Mieczyslaw A Piatyszek

Federico C A Gaeta

Christopher A Foster

Jian Zhang

October Pawlik

Tom Kerley

Jessica Wheeler

Munirathnam Chaguturu

Penelope Burke

Beril Karakas

Telomerase reverse transcriptase (TERT) expression enhancing compounds, and methods for using the same, are provided. In some embodiments, the compounds are azoles, such as such as pyrazoles, imidazoles, triazoles, tetrazoles, thiazoles, isothiazoles, oxazoles, and isoxazoles. In certain embodiments, the azole compound includes an acyl substituent which includes an amide, for example, an alkyl amide. Methods of interest include contacting cells with a TERT expression enhancing effective amount of compound to increase TERT expression in the cells. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.

Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same

8-Hydroxy quinoline derivative compounds for enhancing telomerase reverse transcriptase (TERT) expression, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.

8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression

Methods of treating an age-related disorder in a subject are provided. Aspects of the methods include administering to the subject a nucleic acid vector including a coding sequence for telomerase reverse transcriptase (TERT) and/or telomerase RNA (TR). Gene therapy methods are also provided. Aspects of the invention further include compositions, e.g., nucleic acid vectors and kits, etc., that find use in methods of the invention.

Enhancing health in mammals using telomerase reverse transcriptase gene therapy

Methods and compositions for assaying an agent for TERT promoter modulatory activity are provided. In the subject methods, an agent is contacted with a cell comprising a mutant telomerase structural RNA component (TR) that results in a detectable phenotype in the presence of telomerase reverse transcriptase (TERT). Also provided are compositions, systems and kits thereof, as well as devices, that find use in practicing the subject methods. The subject invention finds use in assaying agents for TERT promoter modulatory activity, such as in a high throughput format.

Assays for TERT promoter modulatory agents using a telomerase structural RNA component

Growing community of inventors

Sparks, NV, United States of America

Lancer K Brown